Cartalax Peptide

Khavinson tripeptide from cartilage extract. Researched for chondroprotective effects, normalizing cartilage metabolism and inhibiting matrix metalloproteinase-mediated collagen degradation in joints.

Cartalax (Ala-Glu-Asp, AED) is a short bioregulatory peptide developed within the Khavinson school of peptide bioregulation. Like other tripeptide bioregulators such as Pinealon (Glu-Asp-Arg) and Vesugen (Lys-Glu-Asp), Cartalax is hypothesised to act through direct, sequence-specific interactions with regulatory regions of DNA and chromatin, modulating the transcription of genes relevant to connective tissue homeostasis.

Epigenetic and Transcriptional Modulation

Research using molecular modelling and binding assays suggests that short peptides of this class can penetrate cell and nuclear membranes and bind to histone proteins and promoter regions of specific genes. For Cartalax, target genes are proposed to include those encoding type II collagen (COL2A1), aggrecan (ACAN), and other extracellular matrix components characteristic of chondrocytes. By influencing methylation patterns and transcription factor recruitment, the peptide is hypothesised to shift gene expression toward an anabolic, matrix-preserving phenotype in cartilage-derived cells.

Chondrocyte Differentiation and Matrix Synthesis

In cultured chondrocytes and mesenchymal stem cell models, Cartalax has been associated with upregulation of chondrogenic markers and increased synthesis of glycosaminoglycans and proteoglycans. This is consistent with the broader Khavinson hypothesis that tissue-derived tripeptides selectively normalise function in the tissues from which their parent polypeptide complex was originally isolated — in this case, cartilage extract.

Modulation of Apoptosis and Oxidative Stress

Cartalax has also been investigated for its effects on chondrocyte apoptosis in aged or stressed cell cultures. Research suggests reduced expression of pro-apoptotic markers such as p53 and caspase-3, along with normalisation of Bcl-2/Bax ratios. These effects parallel observations made with related peptide bioregulators in neuronal (Pinealon), vascular (Vesugen), and thymic (Vilon) tissues, supporting a generalised mechanism of cytoprotection coupled with tissue-specific transcriptional effects.

Inflammatory Pathway Modulation

Preliminary in vitro data suggest that Cartalax may dampen NF-κB-mediated inflammatory signalling in chondrocytes exposed to IL-1β or TNF-α, with corresponding decreases in MMP-13 and ADAMTS-5 expression — enzymes implicated in cartilage matrix degradation. Although this work is preliminary and has not been replicated in large independent laboratories, it provides a plausible mechanistic basis for the chondroprotective effects reported in animal models.

Relationship to Parent Cartilage Bioregulator

Cartalax was designed as the short-peptide analogue of a polypeptide complex isolated from cartilage tissue (Sigmaferon-class preparations). The rationale, common to the Khavinson peptide series, is that the active tripeptide motif retains the tissue-targeting properties of the parent extract while offering improved stability, defined chemistry, and reproducible synthesis. As with other peptides in this family, the proposed mechanisms remain hypotheses supported primarily by single-laboratory data and require independent confirmation.

Cartalax is a short linear tripeptide composed of three standard L-amino acids: alanine, glutamic acid, and aspartic acid. Its compact size and dianionic character at physiological pH influence its solubility, stability, and handling requirements in laboratory work.

Because both glutamate and aspartate side chains carry negative charges at physiological pH, Cartalax is highly hydrophilic and is not expected to cross membranes by passive diffusion at appreciable rates. Mechanistic models proposed by the Khavinson group invoke active transport or carrier-mediated uptake, although the precise transport mechanisms have not been fully characterised. The tripeptide is sensitive to proteolytic degradation by aminopeptidases and dipeptidyl peptidases, which contributes to its short plasma half-life and informs the typical use of repeated dosing regimens in animal protocols.

Cartalax is supplied as a lyophilized white powder under strict laboratory conditions. Because it is a short tripeptide containing acidic residues (glutamic acid and aspartic acid), it is generally well-behaved in aqueous solution but should still be handled with standard peptide laboratory precautions to maintain integrity for research use.

Recommended reconstitution protocol:

1. Allow the sealed vial to equilibrate to room temperature for 20–30 minutes before opening to prevent moisture condensation on the lyophilized powder.
2. Centrifuge the vial briefly (if equipped) to ensure all peptide is at the bottom prior to opening.
3. Select reconstitution solvent: bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection is suitable. Cartalax is highly water-soluble due to its hydrophilic side chains.
4. For a 10 mg vial, add 2 mL of solvent to yield a working concentration of 5 mg/mL. Adjust volume for desired stock concentration.
5. Inject the solvent slowly along the inner wall of the vial — do not direct the stream onto the lyophilized powder cake.
6. Gently swirl or roll the vial between palms until fully dissolved. Do not shake or vortex aggressively, as mechanical agitation may introduce shear stress and bubbles.
7. Allow the reconstituted solution to stand for 1–2 minutes to ensure complete dissolution and dissipation of any micro-bubbles.
8. Inspect visually: the solution should be clear and colorless with no visible particulates.

Compound-specific handling notes:

• Cartalax does not contain methionine, cysteine, or tryptophan, so it is not particularly susceptible to oxidative degradation; however, exposure to direct UV light and prolonged warming should still be avoided.
• The peptide contains free carboxylate groups that make reconstituted solutions mildly acidic. Buffering with sterile PBS (pH 7.4) is acceptable for cell culture applications.
• Use aseptic technique throughout. Cartalax is intended strictly for in vitro and preclinical laboratory research and is not for human or veterinary use.
• Aliquot stock solutions into single-use volumes to minimize freeze-thaw cycles, which can degrade short peptides over time.

All handling should be performed by qualified research personnel using appropriate personal protective equipment (gloves, lab coat, eye protection). Discard any solution showing turbidity, precipitate, or color change.

Proper storage is critical to preserving the structural integrity and biological activity of Cartalax for research applications. Like other Khavinson short peptides, Cartalax (Ala-Glu-Asp) is relatively stable in its lyophilized form but more susceptible to degradation once reconstituted in aqueous solution.

Lyophilized powder storage:

• Long-term (recommended): Store at −20°C or colder in a sealed, desiccated container, protected from light. Under these conditions, lyophilized Cartalax has been reported stable for 24 months or longer.
• Short-term: 2–8°C refrigeration is acceptable for up to 60 days when the vial remains sealed and dry.
• Transit: Brief exposure to ambient room temperature (up to 7–14 days) during shipping does not significantly compromise the lyophilized peptide, owing to the inherent stability of the short tripeptide sequence.

Reconstituted solution storage:

• Store reconstituted Cartalax at 2–8°C and use within 14–21 days for research applications requiring full activity.
• For extended storage of reconstituted solutions, aliquot into low-binding microcentrifuge tubes and freeze at −20°C or −80°C. Avoid more than 2–3 freeze-thaw cycles.
• Protect from direct light by wrapping tubes in foil or using amber vials when possible.

Compound-specific stability notes:

• Cartalax lacks disulfide bonds and oxidation-sensitive residues (Met, Cys, Trp), simplifying its stability profile compared to longer or more complex peptides.
• The acidic side chains of Glu and Asp can undergo slow isomerization or deamidation at extreme pH or elevated temperatures; storing solutions near neutral pH and refrigerated minimizes this.
• Repeated warming and cooling cycles should be avoided, as condensation can introduce moisture into the lyophilized powder and accelerate hydrolysis.
• Always label aliquots with date of reconstitution and lot number for traceability in research records.

When storage best practices are followed, Cartalax maintains the high purity (≥98% HPLC) and biological activity required for reproducible preclinical research outcomes.